What it's for (Indications)
- Silodosin is specifically indicated for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH).
- This condition, common in aging men, involves an enlargement of the prostate gland, which can lead to various lower urinary tract symptoms (LUTS).
- These symptoms typically include urinary hesitancy, a weak or interrupted urinary stream, a feeling of incomplete bladder emptying, straining to urinate, urgency, frequency (especially at night, known as nocturia), and an increased risk of urinary tract infections.
- By targeting the alpha-1A adrenergic receptors predominantly found in the prostate, bladder neck, and prostatic urethra, silodosin helps to alleviate these bothersome symptoms, improving urine flow and reducing the discomfort associated with prostatic obstruction.
- It is important to confirm a diagnosis of BPH and rule out other conditions such as prostate cancer before initiating silodosin therapy.
- This medication effectively addresses the dynamic component of bladder outlet obstruction, which is caused by the smooth muscle tone in the prostate and bladder neck.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage of silodosin for the treatment of benign prostatic hyperplasia (BPH) is 8 mg taken orally once daily with a meal. Administration with food is crucial as it has been shown to reduce the risk of orthostatic hypotension and improve tolerability. For patients with moderate renal impairment (creatinine clearance [CrCl] 30-49 mL/min), the recommended dosage should be reduced to 4 mg once daily, also taken with a meal. Silodosin is contraindicated in patients with severe renal impairment (CrCl < 30 mL/min) due to increased systemic exposure and lack of clinical experience in this population. No dosage adjustment is necessary for patients with mild renal impairment (CrCl 50-79 mL/min). Clinical experience in patients with hepatic impairment is limited, and silodosin is contraindicated in patients with severe hepatic impairment. Prescribing clinicians should always assess renal and hepatic function before initiating and periodically during treatment to ensure appropriate dosing and patient safety. The tablet should be swallowed whole and not crushed or chewed. |
Safety & Warnings
Common Side Effects
- Silodosin is associated with several side effects, the most common and notable being retrograde ejaculation, which affects a significant percentage of male patients (e.
- g.
- , 28% in clinical trials).
- This phenomenon involves semen entering the bladder instead of being expelled through the urethra during ejaculation and is generally reversible upon discontinuation of the medication, though it can be a concern for patients wishing to conceive.
- Other frequent adverse reactions include dizziness, orthostatic hypotension (a drop in blood pressure upon standing, which can lead to syncope), diarrhea, nasal congestion, headache, and nasopharyngitis.
- Less common but potentially serious side effects include priapism (prolonged erection lasting more than 4 hours), which requires immediate medical attention to prevent permanent damage to the penis, and the development of Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery.
- Patients should be advised about these potential effects, particularly the risk of orthostatic hypotension, and counselled to rise slowly from a sitting or lying position to mitigate this risk.
- Regular monitoring for adverse effects is recommended.
Serious Warnings
- Black Box Warning: Silodosin does not carry a formal FDA Black Box Warning. However, it is imperative for healthcare professionals and patients to be aware of several serious warnings and precautions associated with its use, which warrant careful consideration and communication. The most prominent serious concerns include the potential for orthostatic hypotension, which can lead to dizziness, lightheadedness, and syncope, particularly when initiating therapy, upon dose escalation, or when co-administered with other antihypertensive medications or strong CYP3A4 inhibitors. Patients should be advised to avoid situations where injury could result from syncope. Another significant warning is the risk of Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery, which can complicate the procedure and necessitates informing ophthalmologists prior to surgery, allowing for appropriate surgical planning and prophylaxis. Additionally, patients should be evaluated for prostate cancer before initiating treatment with silodosin, as BPH and prostate cancer symptoms can overlap, and silodosin does not treat or prevent prostate cancer. Priapism, a prolonged painful erection lasting more than 4 hours, though rare, requires immediate medical intervention to prevent permanent damage. These serious warnings underscore the importance of thorough patient assessment, education, and ongoing monitoring during silodosin therapy to ensure patient safety.
- Several important warnings and precautions are associated with silodosin use.
- Patients should be explicitly cautioned about the potential for orthostatic hypotension, which can manifest as dizziness, lightheadedness, or syncope, especially upon standing.
- This risk is heightened during initiation of therapy, dosage escalation, or when co-administered with other antihypertensive agents, strong CYP3A4 inhibitors, or other alpha-blockers.
- Furthermore, patients undergoing or planning cataract surgery should inform their ophthalmologist about current or past silodosin use, as it can cause Intraoperative Floppy Iris Syndrome (IFIS), a complication that can increase the risk of surgical complications.
- Prior to initiating silodosin, patients should be evaluated to rule out prostate cancer, as BPH and prostate cancer can present with similar symptoms.
- Silodosin is not indicated for the prevention of prostate cancer.
- Caution is advised in patients with moderate hepatic impairment, and it is contraindicated in severe hepatic impairment due to limited clinical data and increased systemic exposure.
- Similarly, it is contraindicated in severe renal impairment and requires dose adjustment in moderate renal impairment.
- Patients should be warned about the possibility of priapism and instructed to seek immediate medical attention if an erection lasts for more than 4 hours to prevent permanent damage.
- Driving or operating machinery should be avoided until the patient's response to treatment is known.
How it Works (Mechanism of Action)
Silodosin exerts its therapeutic effects by acting as a highly selective antagonist of the alpha-1A adrenergic receptor. These receptors are predominantly located in the smooth muscle of the human prostate, prostatic capsule, bladder neck, and prostatic urethra. By selectively blocking these receptors, silodosin inhibits the sympathetic nervous system-mediated contraction of these smooth muscles. This relaxation leads to a reduction in the dynamic component of bladder outlet obstruction, consequently improving urine flow, reducing bladder pressure, and alleviating the lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). The high selectivity for the alpha-1A subtype, compared to alpha-1B and alpha-1D receptors (which are more prevalent in vascular smooth muscle), theoretically contributes to a lower incidence of generalized cardiovascular side effects, such as systemic vasodilation and associated severe hypotension, compared to non-selective alpha-blockers, although orthostatic hypotension remains a notable adverse effect. This selective action minimizes systemic effects while maximizing local therapeutic benefits.